Commercial success in the Oncology space is more difficult than ever with FDA approvals being at record lows. Coupled with onerous payer demands, it has never been more essential for you to understand the full impact of health economics and comparative effectiveness research. Most notably, how to use this information to ensure your upcoming submission is appropriate to gain reimbursement.

Fundamental to the success of your new medicine is the integration of health economics from the clinical development phase, to ensure that endpoints in clinical trials are a match for what payers are actually prepared to pay for - whilst having maximum value in the marketplace at launch.

Josephine Sollano, Head of Outcomes Research at Pfizer will address these issues head on at the Oncology USA 2010, March 23-24, Boston. She will also be joined by Murray Robinson, SVP Oncology at AVEO pharmaceuticals who will look at the wider picture of how vital it is to encourage increased collaboration between clinical and market access teams for a more cohesive registration and commercialization strategy.

To join the debate click here.

Source:
Claire Poole
eyeforpharma